Limited Edition Pink Pipetman L to Support Cancer Research

  • Gilson Pink PipetmanGilson Pink Pipetman

Gilson announced a new charitable program to benefit cancer research. With each purchase of the specially designed, limited edition Pink Pipetman L pipettes, Gilson will donate a portion of the proceeds to the American Cancer Society (ACS). The special offer will last from October 1, 2018 until December 31, 2018, or while supplies last. Cancer will affect approximately 23.6 million people worldwide by 2030. 

Statement from Nicolas Paris, CEO of Gilson:

“Many of our customers study the causes and potential treatments of cancer, with the goal to ultimately eradicate this terrible disease. We wanted to demonstrate our support of these scientific endeavors and this program seemed like a logical way to achieve that,”

Statement from Melanie Doyle, ACS Program Manager:

“We were excited when Gilson approached us with the idea to offer a special Pipetman pipette with a portion of the sales donated to the American Cancer Society. It is the joint efforts of cancer researchers and lab suppliers like Gilson that will enable us to make a difference in combatting cancer.”

Pipetman L pipettes are one of the most popular continuously adjustable air-displacement pipettes. These lightweight and ergonomically designed pipettes reduce the fatigue associated with manual pipetting, increasing user productivity and reducing injury. Pipetman L pipettes have a volume-locking mechanism to decrease volume errors, improving dispensing accuracy. The limited edition Pink Pipetman L pipettes are available in the commonly used P20L, P200L, and P1000L models. Sales for the ACS donation are only available through the Gilson web site or a direct Gilson sales representative.

For more information on this special program, please visit Gilson here

If you require more information, please contact Gilson here.


Gilson International
Hoenbergstr. 6
65555 Limburg-Offheim
Phone: +49(0) 6431 / 21215-0
Telefax: Fax: +49(0) 6431 / 21215-40

Register now!

The latest information directly via newsletter.

To prevent automated spam submissions leave this field empty.